https://scholars.lib.ntu.edu.tw/handle/123456789/570827
標題: | Hepatitis B reactivation: diagnosis and management | 作者: | SHANG-CHIN HUANG HUNG-CHIH YANG JIA-HORNG KAO |
公開日期: | 2020 | 出版社: | Taylor and Francis Ltd | 卷: | 14 | 期: | 7 | 起(迄)頁: | 565-578 | 來源出版物: | Expert Review of Gastroenterology and Hepatology | 摘要: | Introduction: Hepatitis B virus (HBV) reactivation can be induced by treatments that attenuate the immunological control over HBV, leading to increased morbidity and mortality. The risk of HBV reactivation is determined by host immunity, viral factors, and the type and dose of treatments. Nevertheless, the risk of HBV reactivation for a growing number of novel therapies remains uncertain and needs to be carefully examined. Identification of patients at risk and administration of prophylactic antiviral agents are critical to prevent HBV reactivation. Early diagnosis and initiation of antiviral treatment are the keys to avoid devastating outcomes. Area covered: We summarized the latest evidence and recommendations for risk stratification, early diagnosis, prophylaxis, and management of HBV reactivation. Expert opinion: Universal screening, adequate prophylaxis, and close monitoring are essential for the prevention of HBV reactivation. Risk stratification of patients at risk with appropriate antiviral prophylaxis can prevent HBV reactivation effectively. Several emerging biomarkers have been proved to help determine the risk precisely. Early detection and timely administration of antiviral agents are crucial for management. Further studies on the precision of risk stratification as well as the optimal duration of prophylaxis and treatment are needed to establish an individualized strategy. ? 2020 Informa UK Limited, trading as Taylor & Francis Group. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086922675&doi=10.1080%2f17474124.2020.1774364&partnerID=40&md5=2a11a0b4bb96d947c47d6230db1470ff https://scholars.lib.ntu.edu.tw/handle/123456789/570827 |
ISSN: | 1747-4124 | DOI: | 10.1080/17474124.2020.1774364 | SDG/關鍵字: | afatinib; anthracycline; antivirus agent; bortezomib; CD20 antibody; circular DNA; complementary DNA; covalently closed circular DNA; cytotoxic agent; dasatinib; direct antiviral agent; entecavir; erlotinib; gefitinib; glucocorticoid; imatinib; infliximab; nilotinib; osimertinib; prednisolone; programmed death 1 receptor; protein tyrosine kinase inhibitor; secukinumab; tenofovir alafenamide; tenofovir disoproxil; tocilizumab; tumor necrosis factor inhibitor; unclassified drug; antivirus agent; circular DNA; immunosuppressive agent; virus DNA; antiviral therapy; B lymphocyte; cost effectiveness analysis; disease exacerbation; early diagnosis; hematopoietic stem cell transplantation; hepatitis B; Hepatitis B virus; human; immunization; immunoprophylaxis; infection control; infection prevention; infection risk; liver failure; nonhuman; patient monitoring; pregnancy; Review; risk assessment; screening test; treatment duration; virus reactivation; blood; chronic hepatitis B; drug effect; hepatitis B; Hepatitis B virus; isolation and purification; physiology; virus activation; Antiviral Agents; DNA, Circular; DNA, Viral; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Risk Assessment; Virus Activation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。